Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects by Ellero, C et al.
Original Article: Treatment
Prophylactic use of anti-emetic medications reduced
nausea and vomiting associated with exenatide
treatment: a retrospective analysis of an open-label,
parallel-group, single-dose study in healthy subjects
C. Ellero, J. Han, S. Bhavsar, B. B. Cirincione, M. B. DeYoung, A. L. Gray*, I. Yushmanova
and P. W. Anderson*
Amylin Pharmaceuticals Inc., San Diego, CA and *Lilly USA, LLC, Indianapolis, IN, USA
Accepted 1 July 2010
Abstract
Aims Transientnauseaand,toalesserextent,vomitingarecommonadverseeffectsofexenatidethatcanbemitigatedbydose
titration and usually do not result in treatment discontinuation. This retrospective analysis of data from a phase 1, open-label,
parallel-group,single-dosestudyinhealthysubjectsevaluatedtheeffectoforalanti-emeticsonexenatide-associatednauseaand
vomiting and on the pharmacokinetics of exenatide.
Methods A single subcutaneous dose (10 lg) of exenatide was administered to 120 healthy subjects (19–65 years, BMI
23–35 kg⁄m
2).Incidencesofnauseaandvomitingwerecomparedbetween60subjectspremedicatedwithtwooralanti-emetics
30 min before the exenatide dose and 60 non-premedicated subjects. Similarly, the area under the concentration-time curve
(AUC) and the maximum observed concentration (Cmax) of plasma exenatide concentrations over 8 h post-dose were
compared.
Results Among all subjects [61% male, 32  12 years, body mass index (BMI) 29.1  3.4 kg⁄m
2 (mean  sd)], mild to
moderate nausea was the most frequent adverse event after exenatide dosing. Vomiting was also observed. Subjects
premedicated with anti-emetics experienced signiﬁcantly less nausea and vomiting (16.7 and 6.7%, respectively) vs. non-
premedicatedsubjects(61.7and38.3%,respectively;P-value< 0.0001forbothnauseaandvomiting).Themeanareaunderthe
concentration-timecurveandthemaximumobservedconcentrationAUCandCmaxofplasmaexenatideconcentrationsduring
8 h post-dose were not signiﬁcantly different between groups.
Conclusion Administrationoforalanti-emeticsbeforeasingle10-lgexenatidedosewasassociatedwithsigniﬁcantreductions
intreatment-emergentnauseaandvomiting,withnodiscernibleeffectonthepharmacokineticsofexenatide.Useofanti-emetic
therapy may provide a short-term strategy to minimize the nausea and vomiting associated with exenatide treatment.
Diabet. Med. 27, 1168–1173 (2010)
Keywords anti-emetics, exenatide, nausea, vomiting
Abbreviations AUC, area under the concentration-time curve; BMI, body masss index; Cmax, maximum observed
concentration; GLP-1, glucagon-like peptide 1; HDL, high-density lipoprotein cholesterol; LDL, low-density ipoprotein
cholesterol; MedDRA
 , Medical Dictionary for Regulatory Activities; SD, standard deviation; SE, standard error; tlast,
time of last quantiﬁable sample
Introduction
Exenatide, a ﬁrst-in-class glucagon-like peptide 1 (GLP-1)
receptor agonist, is approved as an adjunct to diet and exercise
and⁄or to some oral anti-diabetic therapies for the treatment of
Type 2 diabetes mellitus. Exenatide improves glycaemic control
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B-cells, suppressing inappropriately elevated glucagon secretion,
slowing gastric emptying, and reducing food intake [1].
Exenatide is administered as a subcutaneous injection at a
startingdoseof5 lgtwicedaily(b.i.d.)whichcanbeincreasedto
10 lg b.i.d.
The most commonly reported adverse event associated
with exenatide b.i.d. treatment is nausea, which in ﬁve
placebo-controlled registration trials in patients with Type 2
diabetes had an incidence ranging from 8 to 44% in exenatide-
treated patients (vs. 0 to 18% for placebo) [1–6]. Vomiting was
also observed, with an incidence of 4 to 13% (vs. 0 to 4%
for placebo) [1–6]. In these trials, less nausea and vomiting were
observed in patients treated only with exenatide than in patients
treated with exenatide and oral anti-diabetic therapies (8 vs.
44% for nausea and 4 vs. 13% for vomiting, respectively) [1–6].
The nausea observed was generally of mild to moderate
intensity, had a higher incidence during the ﬁrst 8 weeks of
therapy and then decreased over time with continued therapy
[1,3–6]. The nausea associated with exenatide therapy is
thought to be the result of slowed gastric emptying, appetite
suppression and stimulation of neural GLP-1 receptors.
Strategies have been investigated to reduce nausea and
vomiting. Gradual dose escalation was shown to be effective in
mitigating nausea and vomiting in an earlier study [7] and was




registration trials, although withdrawals from treatment due to
thesesideeffectsweregenerallylow(from0.6to4%infourtrials
and9%inonetrial)[1–6].Thereisalsoanecdotalevidenceforthe
effectiveness of other strategies implemented by treating
physicians to minimize nausea associated with exenatide
treatment (e.g. reducing food portion size) [8]. Furthermore, it
has been hypothesized that short-term use of anti-emetic
medications may be effective in preventing nausea.
This manuscript reports the results of a retrospective analysis
of data from a phase 1, open-label, parallel-group, single-dose,
pharmacokinetic and safety study conducted in healthy subjects
that included the use of anti-emetic medications in the protocol.
While the study utilized anti-emetics primarily for subject
retention purposes, because the study medication was not
titrated, this post hoc analysis was performed to evaluate
their effectiveness in mitigating the nausea and vomiting





or non-pregnant, non-lactating females; age 19–65 years; and
normal weight, overweight or obese, but otherwise healthy
(BMI 23–35 kg⁄m
2).Main exclusioncriteria included:ahistory
of diabetes mellitus; current hypertension; cardiovascular,
hepatic, renal, gastrointestinal and central nervous system
disease; and previous exposure to exenatide.
Study design and interventions
The study was conducted in 120 subjects enrolled at a single
clinical study site in the USA between March and September
2008.ThestudyprotocolwasapprovedbythelocalInstitutional
Review Board and all subjects provided written informed
consent. The study was conducted in accordance with the
principles described in the Declaration of Helsinki (1964) and
subsequent amendments.
As part of the study, a single subcutaneous injection of 10 lg
exenatide was administered to all subjects. Blood samples were
collectedover8 hfollowingadministrationoftheexenatidedose
tomeasureplasmaexenatideconcentrations.Safetywasassessed
throughout the study by examination of data for adverse events,
clinical laboratory values, vital signs and physical examinations.
The assessment period following the 10-lg exenatide dose was
approximately 1 day.
A higher incidence of nausea was anticipated (compared with
previous studies) because the single dose of study medication
(10 lg) was twice the recommended starting dose of exenatide.
Hence, the protocol allowed administration of up to two
prophylactic oral anti-emetics, at the discretion of the
investigator, approximately 30 min prior to the exenatide
injection in a subgroup of 60 subjects. All subjects in this
subgroup received both metoclopramide (Reglan
  Alaven
Pharmaceutical LLC, Marietta, GA, USA, 10 mg) and ondan-
setron hydrochloride (Zofran
  Glaxo-SmithKline, Research
Triangle Park, NC, USA, 8 mg).
Statistical analyses
Theintent-to-treatpopulationwasdeﬁnedasallenrolledsubjects
who received at least one dose of study medication. Adverse
events were coded using the Medical Dictionary for Regulatory
Activities (MedDRA
 ) version 11.0 (http://www.meddramsso.
com). Treatment-emergent adverse events were deﬁned as those
events that occurred for the ﬁrst time or existed prior to and
worsened during the 1 day following the exenatide dose.
Treatment-emergent adverse events were summarized




the subject’s daily activities; ‘moderate’ if the adverse event
caused a low level of inconvenience to the subject, may have
interfered with daily activities, but was ameliorated by simple
therapeutic measures; or ‘severe’ if the adverse event interrupted
a subject’s daily activities and required systemic drug therapy or
othertreatment.Thepharmacokineticparametersareaunderthe
concentration-time curve from time zero to time of last
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concentration from time zero to time of last quantiﬁable
sample [Cmax(0–tlast)] of plasma exenatide concentrations over
8 h following exenatide dosing were determined using the non-
compartmentalmethodandsummarizeddescriptivelyforintent-
to-treat subjects with valid exenatide pharmacokinetic proﬁles
by anti-emetic treatment group (premedicated and non-
premedicated subjects).
Aposthocanalysiswasperformedtodeterminewhetherthere
were statistically signiﬁcant differences in the incidences of
treatment-emergent nausea and vomiting between subjects who
did and did not receive anti-emetics. P-values were calculated
using the Fisher Exact test. Similarly, the pharmacokinetic
parameters AUC(0–tlast) and Cmax(0–tlast) of plasma exenatide
concentrations over 8 h post-dose were compared between
groups to evaluate the potential effects of the anti-emetics on the
pharmacokinetics of exenatide. P-values were calculated using
Student’s t-test.
Results
Baseline characteristics and subject disposition
All 120 enrolled subjects were included in the intent-to-treat
population. Subjects were: 78% Caucasian, 9% Black, 8%
Hispanic, 3% Native American, 1% Asian and 2% other
ethnicities; 61% male; age 32  12 years, with a screening BMI
of 29.1  3.4 kg⁄m
2 (mean  sd). Demographic and baseline
characteristics in subjects who did and did not receive anti-
emetics were comparable.
Nausea and vomiting adverse events
The adverse event proﬁle during the exenatide assessment
period was similar to that observed in previous studies with
exenatide. Nausea was the most frequent adverse event
reported after the exenatide dose, with 39.2% of subjects
experiencing at least one episode; vomiting occurred in 22.5%
of subjects (Table 1). Both nausea and vomiting adverse events
were of mild to moderate intensity (Table 1). As expected, a
higher incidence of nausea and vomiting was observed in
subjects who had not received anti-emetics, consistent with the
introduction of exenatide at a dose (10 lg) higher than the
recommended starting dose. This group had higher incidences
of nausea and vomiting (61.7 and 38.3%, respectively)
compared with subjects premedicated with anti-emetics (16.7
and 6.7%, respectively) (Table 1 and Fig. 1). The differences
in the incidences of nausea (45%) and vomiting (31.6%)
between premedicated subjects and non-premedicated subjects
were statistically signiﬁcant (P-value < 0.0001 for both nausea
and vomiting) (Fig. 1).
In the group that did not receive anti-emetics, 21 of the
37 subjects who experienced nausea also vomited; in the group
premedicated with anti-emetics, three of the 10 subjects who
experienced nausea also vomited. In addition to receiving
prophylactic anti-emetic medications prior to the exenatide
dose, one of the 60 premedicated subjects was administered a
second dose (4 mg) of ondansetron hydrochloride on the day of
theexenatidedosetotreattreatment-emergentnausea.Likewise,
one subject in the non-premedicated group was given one dose
(4 mg) of ondansetron hydrochloride to treat treatment-
emergent vomiting.
A higher incidence of somnolence was reported in the group
premedicated with anti-emetics (8.3%) compared with the non-
premedicated group (1.7%) (data not shown). Somnolence has
been reported with exenatide treatment post-approval [1] and
had an incidence of 1% in the three registration trials of
exenatide in combination with oral anti-diabetic therapy
(30 weeks each) and up to 6% in other studies of exenatide
[including short-term (28 days), uncontrolled and clinical
Table 1 Treatment-emergent nausea and vomiting adverse events occurring during approximately 1 day following a single subcutaneous exenatide
dose (10 lg) by MedDRA Preferred Term, intensity and anti-emetic treatment [population: ITT (n = 120)]
Preferred term
Intensity
Group by anti-emetic treatment
Non-premedicated (n = 60)* Premedicated (n = 60)* All subjects (n = 120)*
n (%) Events n (%) Events n (%) Events
Nausea 37 (61.7) 41 10 (16.7) 12 47 (39.2) 53
Mild 35 (58.3) 36 8 (13.3) 10 43 (35.8) 46
Moderate 5 (8.3) 5 2 (3.3) 2 7 (5.8) 7
Severe 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Vomiting 23 (38.3) 47 4 (6.7) 5 27 (22.5) 52
Mild 23 (38.3) 36 4 (6.7) 5 27 (22.5) 41
Moderate 2 (3.3) 11 0 (0.0) 0 2 (1.7) 11
Severe 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
*Number of ITT subjects in the corresponding group.
Number of subjects who experienced the adverse event.
Percentages are based on the number of ITT subjects in each group or in ‘All subjects’. Subjects experiencing multiple episodes of a
given adverse event are counted once.
ITT, intent to treat; MedDRA
 , Medical Dictionary for Regulatory Activities version 11.
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drowsiness is a reported adverse effect of both
metoclopramide and ondansetron [9,10].
Plasma exenatide concentrations
Of the 120 intent-to-treat subjects, four subjects in the group
premedicated with anti-emetics were excluded from the
pharmacokinetic analysis because of incomplete pharmaco-
kinetic proﬁles (i.e. less than three quantiﬁable post-dose
measurements), leaving a total of 116 intent-to-treat subjects
evaluable for pharmacokinetic analysis.
There were no statistically signiﬁcant differences in geometric
mean AUC and Cmax of plasma exenatide concentrations during
the8 hfollowingexenatidedosingbetweensubjectswhodidand
did not receive anti-emetics (Table 2), indicating that the
administration of anti-emetic medications had no discernible




signiﬁcant reductions in nausea and vomiting associated with
exenatideadministeredasasingle10-lgdosetohealthysubjects.
The analysis also indicated that concomitant use of anti-emetics
did not alter the pharmacokinetic properties of exenatide,
suggesting that the differences in the incidences of nausea and
vomiting between subjects premedicated and non-premedicated
with anti-emetics were not attributable to differences in plasma
exenatide concentrations in the two groups.
The results of this analysis represent the ﬁrst published data
demonstrating the effectiveness of oral anti-emetic medications
inmitigatingexenatide-inducednauseaandvomiting.Consistent
with previous exenatide trials, nausea and vomiting were
frequently reported adverse events in this study, with
incidences in subjects non-premedicated with anti-emetics
(61.7 and 38.3% for nausea and vomiting, respectively) higher
thanpreviouslyobservedinstudiesofexenatidemonotherapyor
in combination with anti-diabetic therapy (8–44% for nausea
and 4–13% for vomiting) [1], all of which employed dose
titrationfrom5to10 lgb.i.d.Thecurrentanalysisindicatesthat
prophylactic oral anti-emetics led to robust reductions in nausea
and vomiting in the premedicated group following introduction
of exenatide, even at double the recommended starting dose.
(a)
(b)
FIGURE 1 Incidence of nausea (a) and vomiting (b) during approximately
1 day after a single subcutaneous exenatide dose (10 lg) in subjects non-
premedicated and premedicated with anti-emetics. Data are for the intent-
to-treat population (N = 120). Incidence is the percentage of subjects
experiencing the adverse event based on the number of intent-to-treat
subjects in each group. Subjects experiencing multiple episodes of a given
adverse event are counted once. *P < 0.0001 for premedicated vs.
non-premedicated subjects.
Table 2 Pharmacokinetic parameters of plasma exenatide concentrations following a single subcutaneous exenatide dose (10 lg) by anti-emetic
treatment [population: ITT subjects evaluable for pharmacokinetic analysis (n = 116)]
Group by anti-emetic treatment
P-value Non-premedicated (n = 60) Premedicated (n = 56)
Geometric mean AUC(0–tlast) (se) (pg · h⁄ml) 863.53 (30.540) 818.38 (38.065) 0.36
Minimum, maximum 556.6, 1763.3 191.1, 1511.1
Geometric mean Cmax(0–tlast) (se) (pg⁄ml) 242.74 (12.404) 227.36 (15.361) 0.44
Minimum, maximum 109.1, 705.4 92.6, 906.9
Geometric mean = exp{mean[log(X)]}; se of geometric mean = geometric mean · se of mean[log(X)].
AUC(0–tlast), area under the concentration-time curve calculated using the linear trapezoidal method from time zero to tlast; Cmax(0–tlast),
maximum concentration observed during the blood sampling period from time zero to time tlast; ITT, intent to treat; tlast, time of
last quantiﬁable sample during the 8-h post-dose collection period. SE, standard error.
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warrant consideration with regard to extrapolating these results
beyond the context of this study. The study used a single, ﬁxed
dose of exenatide, with oral anti-emetics administered at a
prespeciﬁed time (30 min prior to dosing). Therefore, the study
did not address the effect of repeated administration of anti-
emetics with continued exenatide treatment or the optimal time
of anti-emetic administration relative to exenatide dosing.
Additionally, all subjects in the premedicated group received
both metoclopramide and ondansetron hydrochloride. It is not
known whether administration of either anti-emetic agent alone
would sufﬁce in mitigating nausea and⁄or vomiting. (Although
metoclopramide and ondansetron hydrochloride are not
generally indicated for the treatment of medication-induced
nausea, they were selected because both are commonly used in
clinical practice for this purpose.) Additional potential
limitations of the study design include the subject population,
which comprised healthy individuals whose tolerance to
exenatide may be different from that in patients with diabetes,
and the open-label trial design, which inherently invites the
potential for bias because it can affect patient expectations.
Notwithstanding the aforementioned limitations, the results of
thisanalysisprovideevidencethatprophylacticoralanti-emetics
signiﬁcantly reduced nausea and vomiting following
administration of exenatide and may be relevant to clinical
practice.
Implementing strategies to address the potential nausea and
vomiting adverse events associated with exenatide treatment
could promote patient’s adherence to the treatment regimen and
facilitate the achievement of glycaemic targets [11]. Exenatide is
an effective glucoregulatory agent that also enhances satiety,





suboptimally controlled on such regimens produced signiﬁcant
reductions from baseline to study end in HbA1c, fasting
plasma⁄serum glucose concentrations, body weight (all of
which were sustained over 3 years) and postprandial plasma
glucose concentrations [1–6,12], as well as improvements in
cardiovascular risk factors (blood pressure, high-density
lipoprotein and low-density lipoprotein cholesterol and
triglycerides) and liver injury biomarkers (alanine transaminase
and aspartate aminotransferase), although further investigation
of the latter effects is warranted [12].
Gradual dose escalation at initiation of exenatide therapy is
recommended, having been shown to be effective at mitigating
nausea and vomiting with no loss ofglucoregulatory activity [7].
In clinicalpractice,exenatideisinitiatedat5 lgb.i.d. andcanbe
increased after one month to 10 lg b.i.d., to minimize
gastrointestinal adverse events.
There is also anecdotal evidence of additional strategies that
have been employed to reduce nausea associated with exenatide
[8].Theseincludeeducationofpatientstreatedwithexenatideon
the potential gastrointestinal side effects, including nausea and
sensations of fullness, based on the observation that patients are
better able to manage the nausea if they are forewarned that it
might occur initially, might worsen during dose titration and
shouldgraduallysubsidewithcontinuedtherapy.Othermethods
toeasenauseasuggestedbydiabeteseducatorsinclude:reduction
in food portion size at mealtime to help address the sensation
of fullness and reduce the risk of nausea, given the suspicion
that the sensation reported in clinical trials as nausea may have
been a sensation of fullness for some individuals; administering
the exenatide injection just before a meal within the
recommended 1-h window prior to meals; increasing ﬂuid
intake; symptomatically using antacids; and consuming diet or
sugar-free carbonated beverages [8].
Althoughnauseaismostlyofmildtomoderateintensityandits
incidence and intensity generally decrease after the ﬁrst 8 weeks
of exenatide treatment [1,3–6], prophylactic use of anti-emetics
may provide an additional short-term strategy for the
management of nausea at treatment initiation, during dose
escalation and the ﬁrst weeks of treatment, or in patients who
continue to experience nausea over time. Additional studies are
warranted to investigate the effectiveness of individual anti-
emetic medications on nausea and vomiting with exenatide
treatment, their ideal timing of administration relative to
exenatide dosing, how long to administer these medications
during continued treatment with exenatide and the safety of
longer-term treatment with anti-emetics.
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